N Wolmark

Summary

Affiliation: Allegheny General Hospital
Country: USA

Publications

  1. ncbi The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1)
    N Wolmark
    Department of Human Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    Ann N Y Acad Sci 949:99-108. 2001
  2. ncbi Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Scientific Director s Office, Pittsburgh, PA 15261, USA
    J Clin Oncol 14:1982-92. 1996
  3. ncbi erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
    S Paik
    National Surgical Adjuvant Breast and Bowel Project, Department of Human Oncology, Allegheny University of Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1361-70. 1998
  4. ncbi Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast
    N Wolmark
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 17:3553-9. 1999
  5. ncbi Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
    B Fisher
    B Fisher, National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    J Natl Cancer Inst 93:112-20. 2001
  6. ncbi Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Clin Oncol 16:2672-85. 1998
  7. ncbi Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
    N Wolmark
    N Wolmark, D L Wickerham, E R Fisher, B Fisher, National Surgical Adjuvant Breast and Bowel Project NSABP Operations Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 92:388-96. 2000
  8. ncbi Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    Lancet 353:1993-2000. 1999
  9. ncbi Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    E Mamounas
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA 15212, USA
    J Clin Oncol 17:1349-55. 1999
  10. ncbi Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 17:3374-88. 1999

Research Grants

  1. NSABP COMMUNITY CLINICAL ONCOLOGY PROGRAM RESEARCH BASE
    Norman Wolmark; Fiscal Year: 2007
  2. NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
    Norman Wolmark; Fiscal Year: 2005
  3. NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
    Norman Wolmark; Fiscal Year: 2007
  4. COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Norman Wolmark; Fiscal Year: 2006
  5. NSABP Biological Specimen Banks
    Norman Wolmark; Fiscal Year: 2006
  6. NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
    Norman Wolmark; Fiscal Year: 2006

Detail Information

Publications81

  1. ncbi The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1)
    N Wolmark
    Department of Human Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    Ann N Y Acad Sci 949:99-108. 2001
    ....
  2. ncbi Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Scientific Director s Office, Pittsburgh, PA 15261, USA
    J Clin Oncol 14:1982-92. 1996
    ....
  3. ncbi erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
    S Paik
    National Surgical Adjuvant Breast and Bowel Project, Department of Human Oncology, Allegheny University of Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1361-70. 1998
    ..Overexpression of the erbB-2 protein by breast cancer cells has been suggested to be a predictor of response to doxorubicin. A retrospective study was designed to test this hypothesis...
  4. ncbi Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast
    N Wolmark
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 17:3553-9. 1999
    ..To compare the efficacy of leucovorin-modulated fluorouracil (FU+LV) with that of fluorouracil and levamisole (FU+LEV) or with the combination of FU+LV and levamisole (FU+LV+LEV)...
  5. ncbi Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
    B Fisher
    B Fisher, National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    J Natl Cancer Inst 93:112-20. 2001
    ....
  6. ncbi Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Clin Oncol 16:2672-85. 1998
    ....
  7. ncbi Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
    N Wolmark
    N Wolmark, D L Wickerham, E R Fisher, B Fisher, National Surgical Adjuvant Breast and Bowel Project NSABP Operations Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 92:388-96. 2000
    ..This study was carried out to address this issue. An additional aim was to determine whether leucovorin (LV)-modulated 5-fluorouracil (5-FU) is superior to the combination of 5-FU, semustine, and vincristine (MOF) in men...
  8. ncbi Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    Lancet 353:1993-2000. 1999
    ..We did a double-blind randomised controlled trial to find out whether lumpectomy, radiation therapy, and tamoxifen was of more benefit than lumpectomy and radiation therapy alone for DCIS...
  9. ncbi Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    E Mamounas
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA 15212, USA
    J Clin Oncol 17:1349-55. 1999
    ....
  10. ncbi Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 17:3374-88. 1999
    ..B-25 was initiated to determine whether further intensifying and increasing the cyclophosphamide dose would yield more favorable results...
  11. ncbi HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
    S Paik
    Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Allegheny General Hospital, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 92:1991-8. 2000
    ..We hypothesized that AC would be superior to CMF only in the HER2-positive patients...
  12. ncbi Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    J Clin Oncol 19:931-42. 2001
    ....
  13. ncbi Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials
    Greg Yothers
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, One Sterling Plaza, 201 N Craig St, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 103:1498-506. 2011
    ..We investigated whether disparities in survival and related endpoints would persist when patients were treated with identical therapies in controlled clinical trials...
  14. ncbi Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Allegheny University of the Health Sciences, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 90:1371-88. 1998
    ..To test this hypothesis, the National Surgical Adjuvant Breast and Bowel Project initiated the Breast Cancer Prevention Trial (P-1) in 1992...
  15. ncbi Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06
    E R Fisher
    National Surgical Adjuvant Breast and Bowel Project Pathology Center, Pittsburgh, Pennsylvania, USA
    Cancer 91:1679-87. 2001
    ....
  16. ncbi National Surgical Adjuvant Breast and Bowel Project trials in colon cancer
    N Wolmark
    National Surgical Adjuvant Breast and Bowel Project Operations Center, Pittsburgh, PA 15212, USA
    Semin Oncol 28:9-13. 2001
    ....
  17. ncbi Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer
    T B Julian
    Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Am J Surg 182:407-10. 2001
    ..The sentinel node accurately predicted metastatic disease in the axilla. IHC studies failed to detect any additional micrometastases. This diagnostic technique may provide treatment guidance for patients after neoadjuvant therapy...
  18. ncbi Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Semin Oncol 28:400-18. 2001
    ..It does suggest, however, that, in the treatment of DCIS, the appropriate use of current and better therapeutic agents that become available could diminish the significance of breast cancer as a public health problem...
  19. ncbi Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers
    L E Janocko
    Department of Human Genetics MCP/Hahnemann University, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212, USA
    Cytometry 46:136-49. 2001
    ..Furthermore, the same patterns of accumulation of multiple genophenotypic abnormalities are recapitulated in different tumors...
  20. ncbi Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Victor G Vogel
    Magee Womens Hospital, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 3221, USA
    JAMA 295:2727-41. 2006
    ..Tamoxifen is approved for the reduction of breast cancer risk, and raloxifene has demonstrated a reduced risk of breast cancer in trials of older women with osteoporosis...
  21. ncbi Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
    ..The relationship between the RS and chemotherapy benefit is not known...
  22. ncbi Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    Barry C Lembersky
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:2059-64. 2006
    ..CONCLUSION: UFT+LV achieved similar DFS and OS when compared with an intravenous, weekly, bolus FU+LV regimen. The two regimens were equitoxic and generally well tolerated...
  23. ncbi Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 24:2028-37. 2006
    ..Locoregional failure after breast-conserving surgery is associated with increased risk of distant disease and death. The magnitude of this risk in patients receiving chemotherapy has not been adequately characterized...
  24. ncbi Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Clin Oncol 24:2019-27. 2006
    ..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)...
  25. ncbi Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1)
    Mary S Beattie
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, USA
    J Natl Cancer Inst 98:110-5. 2006
    ..The purpose of this study was to determine whether sex hormone levels were associated with breast cancer risk and with response to tamoxifen in a high-risk population...
  26. ncbi Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Bernard Fisher
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Natl Cancer Inst 97:1652-62. 2005
    ..Side effects of varying clinical significance were observed. The trial was unblinded because of the positive results, and follow-up continued. This report updates our initial findings...
  27. ncbi Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
    Daniel J Sargent
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:8664-70. 2005
    ..A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice...
  28. ncbi Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast can
    Elizabeth Tan-Chiu
    National Surgical Adjuvant Breast and Bowel Project (NSABP, University of Pittsburgh, PA, USA
    J Clin Oncol 23:7811-9. 2005
    ..CONCLUSION: Administering trastuzumab with paclitaxel after AC increases incidence of CHF and lesser CD. Potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy...
  29. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)..
  30. ncbi Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 23:3686-96. 2005
    ....
  31. ncbi Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial
    Eva Chalas
    Department of Obstetrics, Gynecology and Reproductive Medicine, Stony Brook University, State University of New York, Stony Brook, NY
    Am J Obstet Gynecol 192:1230-7; discussion 1237-9. 2005
    ..This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project...
  32. ncbi Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial
    Neil Abramson
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Natl Cancer Inst 98:904-10. 2006
    ..However, the involvement of hypercoagulability factors in this association is unclear...
  33. ncbi Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel
    Alphonse G Taghian
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Graduate School of Public Health, University of Pittsburgh, PA, USA
    J Clin Oncol 24:3927-32. 2006
    ..In this study, we assess patterns of locoregional failure (LRF) in LN-negative patients who underwent mastectomy, either with or without adjuvant chemotherapy or hormonal therapy and without postmastectomy radiation therapy (PMRT)...
  34. ncbi Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer
    James J Dignam
    Department of Health Studies, 5841 South Maryland Ave, MC 2007, University of Chicago, Chicago, IL 60637, USA
    J Natl Cancer Inst 98:1647-54. 2006
    ..We investigated the association of body mass index (BMI) with outcomes after colon cancer in patients from cooperative group clinical trials...
  35. ncbi A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
    Irene L Wapnir
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    Clin Breast Cancer 8:287-92. 2008
    ..Although multidrug regimens are preferred, the agents, doses, and use of supportive therapy are at the discretion of the investigator...
  36. ncbi Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group
    John T Hamm
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Philadelphia, PA, USA
    Clin Breast Cancer 8:257-63. 2008
    ..This trial also evaluated the feasibility of tissue collection for gene-expression profiling...
  37. ncbi Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
    J Clin Oncol 26:1965-71. 2008
    ....
  38. ncbi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS...
  39. ncbi Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania, USA
    Cancer 110:1929-36. 2007
    ..Uncertainties continue to exist concerning the outcomes and management of small (T1a/b N0 M0) invasive breast cancers...
  40. ncbi Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women
    David Cella
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, PA, USA
    Breast Cancer Res Treat 109:515-26. 2008
    ..To evaluate scalability of a symptom scale administered to women enrolled in the Breast Cancer Prevention Trial (BCPT) (P-1) conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP)...
  41. ncbi Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
    David N Krag
    University of Vermont, College of Medicine, Burlington, VT 05405 0068, USA
    Lancet Oncol 8:881-8. 2007
    ..The aim of this paper is to report the technical success and accuracy of SLN resection plus ALND versus SLN resection alone...
  42. ncbi Pathologic variables predictive of breast events in patients with ductal carcinoma in situ
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    Am J Clin Pathol 128:86-91. 2007
    ..The similar predictive role of comedo necrosis in this study and that reported previously from NSABP B-17 (total of 2,079 patients) strongly supports its role as a simple high-risk predictor for ipsilateral breast tumor recurrences...
  43. ncbi Is sentinel node biopsy necessary in conservatively treated DCIS?
    Thomas B Julian
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, Pennsylvania, USA
    Ann Surg Oncol 14:2202-8. 2007
    ..Its use in patients with DCIS versus local excision (LE), observation, and/or breast irradiation remains in question...
  44. ncbi Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 25:2198-204. 2007
    ..This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer...
  45. ncbi Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA 15213, USA
    J Clin Oncol 25:2205-11. 2007
    ..Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments...
  46. ncbi NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-fr
    Eleftherios P Mamounas
    Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
    Clin Breast Cancer 7:416-21. 2006
  47. ncbi Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project NSABP Operations and Biostatistical Centers, Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 295:2742-51. 2006
    ..Tamoxifen has been approved for breast cancer risk reduction in high-risk women, but how raloxifene compares with tamoxifen is unknown...
  48. ncbi Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Eleftherios P Mamounas
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    J Clin Oncol 23:2694-702. 2005
    ..Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherapy is limited. We examined the feasibility and accuracy of this procedure within a randomized trial in patients treated with neoadjuvant chemotherapy...
  49. ncbi Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ
    Edwin R Fisher
    Pathology Center, National Surgical Adjuvant Breast and Bowel Project Pathology Center, Pittsburgh, Pennsylvania, USA
    Cancer 100:238-44. 2004
    ..The current report represents a 12-year clinicopathologic update of an earlier 5-year analysis of 180 patients with lobular carcinoma in situ (LCIS) who were treated with local excision and subsequent surveillance only...
  50. ncbi The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    Virginia Commonwealth University, Medical College of Virginia School of Medicine, Richmond, VA, USA
    J Clin Oncol 21:4165-74. 2003
    ....
  51. ncbi The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06
    Melvin Deutsch
    Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Cancer 98:1362-8. 2003
    ....
  52. ncbi Effects of tamoxifen on benign breast disease in women at high risk for breast cancer
    Elizabeth Tan-Chiu
    Cancer Research Network, 350 84th Avenue, Suite 305, Plantation, FL 33324, USA
    J Natl Cancer Inst 95:302-7. 2003
    ..We examined the effect of tamoxifen treatment on the incidence of benign breast disease and the number of breast biopsies in the same group of women...
  53. ncbi Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study
    Carmen J Allegra
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 2440, USA
    J Clin Oncol 21:241-50. 2003
    ..To define the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with stage II and III colon carcinoma...
  54. ncbi Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    N Engl J Med 347:1233-41. 2002
    ..In 1976, we initiated a randomized trial to determine whether lumpectomy with or without radiation therapy was as effective as total mastectomy for the treatment of invasive breast cancer...
  55. ncbi Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer
    Thomas B Julian
    Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    Am J Surg 184:315-7. 2002
    ....
  56. ncbi Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
    J Clin Oncol 20:4141-9. 2002
    ....
  57. ncbi Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project Pathology Center, Pittsburgh, Pennsylvania, USA
    Cancer 95:681-95. 2002
    ..The adverse relation between such small metastases and OS and DFS after preop AC appears to be related to the timing of the chemotherapy administration rather than any pathobiologic reasons...
  58. ncbi Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212 5234, USA
    N Engl J Med 347:567-75. 2002
    ..We report 25-year findings of a randomized trial initiated in 1971 to determine whether less extensive surgery with or without radiation therapy was as effective as the Halsted radical mastectomy...
  59. ncbi The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial
    Victor G Vogel
    The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc, Pittsburgh, PA, USA
    Clin Breast Cancer 3:153-9. 2002
    ..0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast..
  60. ncbi NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial
    David N Krag
    Department of Surgery, University of Vermont, Burlington, Vermont, USA
    Ann Surg Oncol 11:208S-10S. 2004
    ..A secondary aim of the B32 trial is to evaluate whether patients with "occult" metastases in the SNs have worse survival. Accrual is taking place at 73 institutions in North America, and 217 surgeons are enrolling patients...
  61. ncbi Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
    J Clin Oncol 22:1785-96. 2004
    ..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
  62. ncbi Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials
    Bernard Fisher
    National Surgical Adjuvant Breast and Bowel Project, Operations Center, USA
    J Natl Cancer Inst 96:1823-31. 2004
    ..This report presents updated findings from those trials, relates the results to age and menopausal status, and estimates the extent of progress made in treating such patients...
  63. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  64. ncbi Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project Pathology Center and Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania 15212, USA
    Cancer 103:164-73. 2005
    ..The authors attempted to resolve the dilemma posed by the lack of unanimity concerning the optimal immunohistochemical (IHC) method for determining and scoring estrogen receptor (ER) and progesterone receptor (PR)...
  65. ncbi Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized c
    Alphonse Taghian
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostastical Centers, University of Pittsburgh, Graduate School of Public Health, PA, USA
    J Clin Oncol 22:4247-54. 2004
    ....
  66. ncbi Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials
    Bernard Fisher
    Operations Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Lancet 364:858-68. 2004
    ..We present long-term findings from those trials and relate them to age, menopausal status, and tumour oestrogen-receptor concentrations. We also discuss the extent of progress made in the treatment of such patients...
  67. ncbi Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23
    Stephanie R Land
    NSABP Biostatistical Center, Pittsburgh, USA Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
    Breast Cancer Res Treat 86:153-64. 2004
    ..QOL information was considered especially relevant given the possibility that the two chemotherapy regimens would prove equivalent in terms of clinical outcome...
  68. ncbi Lower-category benign breast disease and the risk of invasive breast cancer
    Jiping Wang
    Biostatistical Center, National Surgical Breast and Bowel Project and Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Natl Cancer Inst 96:616-20. 2004
    ..This report evaluates the risk of breast cancer associated with this lower-category BBD (LC-BBD)...
  69. ncbi Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01
    Roy E Smith
    NSABP Operations Center, Pittsburgh, PA RES, NM NSABP Biostatistical Center, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 96:1128-32. 2004
    ..We now provide a 10-year update of this trial...
  70. ncbi Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer
    Sandra M Swain
    National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 96:516-23. 2004
    ....
  71. ncbi Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience
    Soonmyung Paik
    National Surgical Adjuvant Breast and Bowel Project NSABP Operation Center, Pittsburgh, PA 15212, USA
    J Natl Cancer Inst 94:852-4. 2002
    ..This report provides a snapshot of the quality of HER2 assays performed in laboratories nationwide...
  72. ncbi Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04
    Norman Wolmark
    J Clin Oncol 23:933-4; author reply 934-5. 2005
  73. ncbi HER2 status and benefit from adjuvant trastuzumab in breast cancer
    Soonmyung Paik
    N Engl J Med 358:1409-11. 2008
  74. ncbi Is tamoxifen a risk factor for retinal vaso-occlusive disease?
    Michael B Gorin
    Department of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Retina 25:523-6. 2005
  75. ncbi Lack of influence of cytokeratin-positive mini micrometastases in "Negative Node" patients with colorectal cancer: findings from the national surgical adjuvant breast and bowel projects protocols R-01 and C-01
    Edwin R Fisher
    National Surgical Adjuvant Breast and Bowel Project (NSABP, Pathology, Biostatistical and Headquarters Centers, Pittsburgh, Pennsylvania, USA
    Dis Colon Rectum 46:1021-5; discussion 1025-6. 2003
    ....
  76. ncbi Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
    Cancer 110:1945-50. 2007
    ..Cases of severe gastrointestinal toxicity were monitored prospectively during NSABP C-07, a randomized clinical trial of adjuvant therapy for patients with stage II/III colon cancer...
  77. ncbi Letrozole after tamoxifen for breast cancer--what is the price of success?
    John Bryant
    N Engl J Med 349:1855-7. 2003
  78. ncbi Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06
    Jacek A Kopec
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Clin Oncol 25:424-30. 2007
    ....
  79. ncbi A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer
    Sheri K Dennison
    Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
    Invest New Drugs 25:545-51. 2007
    ..The combination of gefitinib and docetaxel is an active regimen in patients with previously untreated metastatic breast cancer, with a clinical benefit rate and toxicity profile in the range of that reported for docetaxel alone...
  80. ncbi Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials
    James J Dignam
    Department of Health Studies, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    J Clin Oncol 21:413-20. 2003
    ..The randomized trial setting enhances uniformity in disease stage and treatment plan among all participants...
  81. ncbi Association of tamoxifen and uterine sarcoma
    D Lawrence Wickerham
    J Clin Oncol 20:2758-60. 2002

Research Grants14

  1. NSABP COMMUNITY CLINICAL ONCOLOGY PROGRAM RESEARCH BASE
    Norman Wolmark; Fiscal Year: 2007
    ....
  2. NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
    Norman Wolmark; Fiscal Year: 2005
    ..abstract_text> ..
  3. NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
    Norman Wolmark; Fiscal Year: 2007
    ..abstract_text> ..
  4. COMMUNITY CLINICAL ONCOLOGY PROGRAM
    Norman Wolmark; Fiscal Year: 2006
    ..abstract_text> ..
  5. NSABP Biological Specimen Banks
    Norman Wolmark; Fiscal Year: 2006
    ..Continued support of these relevant, important activities is essential for the well-being of cancer patients and is critical to the success of both the NSABP's and the NCI's missions. ..
  6. NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT
    Norman Wolmark; Fiscal Year: 2006
    ....